A former prospective multi-center cohort study reported a notable decrease in breast cancer risk in both BRCA1 and 2 pathogenic variant carriers associated with RRBSO, resulting in a decrease in breast-cancer-specific mortality of more than 50% (HR = 0.44; 95% CI, 0.26–0.76) [69]. This evidence concerns the gene BRCA1 and breast carcinoma.